Publications
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science, First Faculty of Medicine
- Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
- Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report2015 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Tolerancy of treatment with afatinib on our group of patients2014 | Faculty of Medicine in Pilsen
- Lung adenocarcinoma with two simultaneous driving mutations2013 | Faculty of Medicine in Pilsen
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Third Faculty of Medicine
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Medicine in Pilsen, Faculty of Science, Central Library of Charles University
Loading network view...